<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Immuron Ltd — News on 6ix</title>
<link>https://6ix.com/company/immuron-ltd</link>
<description>Latest news and press releases for Immuron Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 10:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/immuron-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683666e178dffbe2df15e1d6.webp</url>
<title>Immuron Ltd</title>
<link>https://6ix.com/company/immuron-ltd</link>
</image>
<item>
<title>Immuron Double Digit 3Q Sales Growth</title>
<link>https://6ix.com/company/immuron-ltd/news/immuron-double-digit-3q-sales-growth</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/immuron-double-digit-3q-sales-growth</guid>
<pubDate>Fri, 17 Apr 2026 10:00:00 GMT</pubDate>
<description>Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp)YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp) Australia Q3 sales AUD$0.9 million up 15% on prior comparative period (pcp)YTD Mar 2026 sales AUD$4.2 million up 14% on prior comparative period (pcp) Canada Q3 sales AUD$0.1 million up >100% on prior comparative period (pcp)Q3 sales up 82% on prior quarter; initial sales to Jean Coutu, QuebecYTD Mar 2026 sales AUD$0.1 mi</description>
</item>
<item>
<title>Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference</title>
<link>https://6ix.com/company/immuron-ltd/news/immuron-ceo-steven-lydeamore-presentation-at-coffee-microcaps-conference-3</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/immuron-ceo-steven-lydeamore-presentation-at-coffee-microcaps-conference-3</guid>
<pubDate>Thu, 05 Mar 2026 11:00:00 GMT</pubDate>
<description>MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on Thursday 5th March 2026 (11:00am – 11:30am Australian Eastern Time). A copy of the presentation slide deck is available on the Company’s website: https://investors.immuron.com.au/announcements/7418301 C</description>
</item>
<item>
<title>Strategic Update and HY26 Results</title>
<link>https://6ix.com/company/immuron-ltd/news/strategic-update-and-hy26-results</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/strategic-update-and-hy26-results</guid>
<pubDate>Wed, 25 Feb 2026 11:03:14 GMT</pubDate>
<description>Strategic Update and HY26 Results</description>
</item>
<item>
<title>Immuron Reports HY26 Results and Strategic Reset</title>
<link>https://6ix.com/company/immuron-ltd/news/immuron-reports-hy26-results-and-strategic-reset</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/immuron-reports-hy26-results-and-strategic-reset</guid>
<pubDate>Wed, 25 Feb 2026 11:00:00 GMT</pubDate>
<description>Highlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash (AUD $10.0 million) to fund operating activities. Includes AUD $7.3 million (net) raised at an average price of A$0.0803 (IMRN USD$2.0923).Validated Platform: The "Hyper-Immune" platform is versatile. Beyond traveler’s diarrhea (Travelan®), the company is moving into high-value clinical targets</description>
</item>
<item>
<title>Appendix 4D and Half Year Report</title>
<link>https://6ix.com/company/immuron-ltd/news/appendix-4d-and-half-year-report-77</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/appendix-4d-and-half-year-report-77</guid>
<pubDate>Wed, 25 Feb 2026 10:10:09 GMT</pubDate>
<description>Appendix 4D and Half Year Report</description>
</item>
<item>
<title>Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream</title>
<link>https://6ix.com/company/immuron-ltd/news/presenting-on-emerging-growth-conference-89-day-2-on-january-22-register-to-live-stream-3</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/presenting-on-emerging-growth-conference-89-day-2-on-january-22-register-to-live-stream-3</guid>
<pubDate>Wed, 21 Jan 2026 12:00:00 GMT</pubDate>
<description>MIAMI, Jan. 21, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presen</description>
</item>
<item>
<title>Immuron Reports Continued Sales Growth</title>
<link>https://6ix.com/company/immuron-ltd/news/immuron-reports-continued-sales-growth-110000414</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/immuron-reports-continued-sales-growth-110000414</guid>
<pubDate>Mon, 19 Jan 2026 11:00:00 GMT</pubDate>
<description>Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp)Q2 sales AUD$2.2 million up 11% on prior quarter Australia H1 sales AUD$3.3 million up 13% on prior comparative period (pcp)Q2 sales AUD$1.7 million up 11% on prior quarterAustralian launch of ProIBS® Canada H1 sales AUD$56 thousand down 85% on prior comparative period (pcp)Q2 sales AUD$42 thousand up 191% on prior quarter USA H1 sales AUD$0.9 million up 17% on prior comparative period (pcp)Q2 sa</description>
</item>
<item>
<title>Uniformed Services University to Release Topline Data</title>
<link>https://6ix.com/company/immuron-ltd/news/uniformed-services-university-to-release-topline-data</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/uniformed-services-university-to-release-topline-data</guid>
<pubDate>Wed, 10 Dec 2025 03:32:05 GMT</pubDate>
<description>Uniformed Services University to Release Topline Data</description>
</item>
<item>
<title>Immuron New U.S. Department of Defense Award & Clinical Trial Update</title>
<link>https://6ix.com/company/immuron-ltd/news/immuron-u-department-defense-award-110000090</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/immuron-u-department-defense-award-110000090</guid>
<pubDate>Wed, 03 Dec 2025 11:00:00 GMT</pubDate>
<description>Highlights: New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and ShigellaUniformed Services University P2TD clinical study update MELBOURNE, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, announces a new research agreement with the Naval Medical Research Command (NMRC) and the Walter Reed Army Institute of Research (WRAIR), Silver Spring, M</description>
</item>
<item>
<title>Immuron IMM-529 IND approved by FDA</title>
<link>https://6ix.com/company/immuron-ltd/news/immuron-imm-529-ind-approved-110000783</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/immuron-imm-529-ind-approved-110000783</guid>
<pubDate>Wed, 05 Nov 2025 11:00:00 GMT</pubDate>
<description>Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceedFDA assigned an IND number (032095) for the IMM-529 application IND 32095 is Immuron’s Investigational new drug (IND) application for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) and is now active MELBOURNE, Australia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limit</description>
</item>
<item>
<title>IMM-529 IND approved by FDA</title>
<link>https://6ix.com/company/immuron-ltd/news/imm-529-ind-approved-by-fda</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/imm-529-ind-approved-by-fda</guid>
<pubDate>Wed, 05 Nov 2025 09:26:02 GMT</pubDate>
<description>IMM-529 IND approved by FDA</description>
</item>
<item>
<title>Immuron Announces Clinical Trial Update</title>
<link>https://6ix.com/company/immuron-ltd/news/immuron-announces-clinical-trial-100000084</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/immuron-announces-clinical-trial-100000084</guid>
<pubDate>Fri, 31 Oct 2025 10:00:00 GMT</pubDate>
<description>IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data delayed to the end of November due to U.S government shutdown MELBOURNE, Australia, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company provides a clinical trial update on Travelan® and IMM-529. IMM-529 IND (</description>
</item>
<item>
<title>Clinical Trial Update</title>
<link>https://6ix.com/company/immuron-ltd/news/clinical-trial-update-2</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/clinical-trial-update-2</guid>
<pubDate>Fri, 31 Oct 2025 02:44:21 GMT</pubDate>
<description>Clinical Trial Update</description>
</item>
<item>
<title>Immuron launch PROIBS for IBS</title>
<link>https://6ix.com/company/immuron-ltd/news/immuron-launch-proibs-for-ibs</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/immuron-launch-proibs-for-ibs</guid>
<pubDate>Fri, 24 Oct 2025 02:54:17 GMT</pubDate>
<description>Immuron launch PROIBS for IBS</description>
</item>
<item>
<title>Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.</title>
<link>https://6ix.com/company/immuron-ltd/news/presenting-on-emerging-growth-conference-87-day-1-on-october-22-register-to-live-stream-6</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/presenting-on-emerging-growth-conference-87-day-1-on-october-22-register-to-live-stream-6</guid>
<pubDate>Tue, 21 Oct 2025 11:00:00 GMT</pubDate>
<description>MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp</description>
</item>
<item>
<title>Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target</title>
<link>https://6ix.com/company/immuron-ltd/news/emerging-growth-research-initiates-coverage-on-immuron-limited-with-a-buy-extended-rating-and-dollar400-price-target</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/emerging-growth-research-initiates-coverage-on-immuron-limited-with-a-buy-extended-rating-and-dollar400-price-target</guid>
<pubDate>Fri, 17 Oct 2025 15:07:00 GMT</pubDate>
<description>New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on Immuron Limited (Nasdaq: IMRN) with a Buy-Extended rating and a 12-month price target of $4.00, representing over 80% upside from the Company's recent closing price of $2.20.The initiation report highlights Immuron's proprietary polyclonal antibody platform, strong revenue growth from its over-the-counter product Travelan®, and an expanding clinical pipeline addressing</description>
</item>
<item>
<title>Immuron Q1 FY26 YoY growth</title>
<link>https://6ix.com/company/immuron-ltd/news/immuron-q1-fy26-yoy-growth-100000753</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/immuron-q1-fy26-yoy-growth-100000753</guid>
<pubDate>Mon, 13 Oct 2025 10:00:00 GMT</pubDate>
<description>Sales Highlights (unaudited): Global•Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp) Australia•Q1 sales AUD$1.6 million up 52% on pcp Canada•Q1 sales AUD$0.0 million down 92% on pcp USA•Q1 sales AUD$0.4 million up 44% on pcp MELBOURNE, Australia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-count</description>
</item>
<item>
<title>Immuron Submits IMM-529 IND to FDA</title>
<link>https://6ix.com/company/immuron-ltd/news/immuron-submits-imm-529-ind-100000577</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/immuron-submits-imm-529-ind-100000577</guid>
<pubDate>Wed, 08 Oct 2025 10:00:00 GMT</pubDate>
<description>Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 MELBOURNE, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that it has submitted an Investigational New Drug (IND) application to the United States</description>
</item>
<item>
<title>Immuron Letter to Shareholders – Projects Update</title>
<link>https://6ix.com/company/immuron-ltd/news/immuron-letter-shareholders-projects-100000963</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/immuron-letter-shareholders-projects-100000963</guid>
<pubDate>Thu, 02 Oct 2025 10:00:00 GMT</pubDate>
<description>Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical study conducted by Uniformed Services University are anticipated in October 2025 IMM-529 Regulatory Milestone: Immuron plans to submit an Investigational New Drug (IND) application to the U.S. FDA for IMM-529 (Clostridiodes difficile infection) in mid-October 2025ProIBS® Commercial Launch: Th</description>
</item>
<item>
<title>FY25 Results Presentation</title>
<link>https://6ix.com/company/immuron-ltd/news/fy25-results-presentation-77</link>
<guid isPermaLink="true">https://6ix.com/company/immuron-ltd/news/fy25-results-presentation-77</guid>
<pubDate>Fri, 29 Aug 2025 03:57:19 GMT</pubDate>
<description>FY25 Results Presentation</description>
</item>
</channel>
</rss>